About this trial

This study aims to conduct a randomized, double blind, randomised controlled multicentre trial of sirolimus drug coated balloon versus standard percutaneous transluminal angioplasty for the treatment of below the knee arterial disease.

Eligibility criteria

Qualifiers

Age ≥ 21 years or minimum age

Rutherford class 4 to 6 in the target limb

Single or sequential de novo or re-stenotic lesions (stenosis of > 50% or occlusions) from 2 to 20cm in the proximal 200mm of below the knee arteries. Lesion is considered as one lesion if there is maximum of 30mm gap between lesions at discretion of investigator. Below the knee arteries are tibioperoneal trunk, anterior tibial artery, posterior tibial artery and peroneal artery

Inflow free from flow limiting lesions (<50% stenosis) confirmed by duplex or angiography. Subjects with flow limiting inflow lesions (>50% stenosis) can be included if lesion had been treated successfully (<30% residual stenosis) before or during the index procedure.

Disqualifiers

Comorbid conditions limiting life expectancy ≤ 1 year

Subject is currently participating in another investigational drug or device study that has not reached first primary endpoint yet

Subject is pregnant or planning to become pregnant during the course of the study

Heel gangrene

Trial design

Treatments tested in this trial

  • MagicTouch PTA Sirolimus drug coated balloon
  • POBA balloon

Treatment groups

219 Participants
are divided into 2 treatment groups

Locations

20
Singapore
Khoo Teck Puat Hospital Singapore Singapore
National University Hospital Singapore Singapore
Ng Teng Fong General Hospital Singapore Singapore
Sengkang General Hospital Singapore Singapore

Sponsors and collaborators

Concept Medical Inc.

Lead sponsor